estriol 3-sulfate 16-glucuronide: estriol conjugate; RN given refers to beta-D glucopyranosiduronic acid (16alpha,17beta)-isomer
ID Source | ID |
---|---|
PubMed CID | 151223 |
CHEBI ID | 88727 |
SCHEMBL ID | 3448859 |
MeSH ID | M0090487 |
Synonym |
---|
estriol 3-sulfate 16-glucuronide |
(2s,3s,4s,5r)-3,4,5-trihydroxy-6-[[(8r,9s,13s,14s,16r,17r)-17-hydroxy-13-methyl-3-sulfooxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]oxy]oxane-2-carboxylic acid |
estriol-3-sulfate-16-glucosiduronate |
estriol-3-sulfate-16alpha-glucosiduronate |
4661-65-8 |
beta-d-glucopyranosiduronic acid, (16alpha,17beta)-17-hydroxy-3-(sulfooxy)estra-1,3,5(10)-trien-16-yl |
SCHEMBL3448859 |
CHEBI:88727 |
(16alpha,17beta)-17-hydroxy-3-(sulfooxy)estra-1,3,5(10)-trien-16-yl-beta-d-glucopyranosiduronic acid |
estriol 3-sulphate 16alpha-glucuronoside |
estriol 3-sulfate 16-glucuronoside |
estriol 3-sulphate 16-glucuronoside |
estriol 3-sulphate 16alpha-glucuronide |
estriol 3-sulphate 16-glucuronide |
(16alpha,17beta)-17-hydroxy-3-(sulfooxy)estra-1,3,5(10)-trien-16-yl-beta-delta-glucopyranosiduronic acid |
estriol 3-sulfate 16alpha-glucuronoside |
Q27160645 |
Class | Description |
---|---|
steroid saponin | Any saponin derived from a hydroxysteroid. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |